01

Ibrutinib

Brand: Imbruvica · 222K Part D claims (CY24) · 29K beneficiaries · First FDA approval: 2013-11-13

Brand-only (no generics) 1956 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $3.48B

Class share

13%

of class CY24 spend

View profile →

02

Ruxolitinib

Brand: JAKAFI · 280K Part D claims (CY24) · 62K beneficiaries · First FDA approval: 2011-11-16

Brand-only (no generics) 1642 plans require PA

Low NADAC$34.14

→

Avg plan cost$34.14

Part D spend $3.38B 1× spread, current vs floor

Class share

13%

of class CY24 spend

View profile →

03

Palbociclib

Brand: Ibrance · 211K Part D claims (CY24) · 33K beneficiaries · First FDA approval: 2015-02-03

Brand-only (no generics) 1962 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $3.30B

Class share

12%

of class CY24 spend

View profile →

04

Zanubrutinib

Brand: BRUKINSA · 219K Part D claims (CY24) · 37K beneficiaries · First FDA approval: 2019-11-14

Brand-only (no generics) 327 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $2.91B

Class share

11%

of class CY24 spend

View profile →

05

Acalabrutinib

Brand: CALQUENCE · 203K Part D claims (CY24) · 33K beneficiaries · First FDA approval: 2017-10-31

Brand-only (no generics) 326 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $2.85B

Class share

11%

of class CY24 spend

View profile →

06

Osimertinib

Brand: TAGRISSO · 158K Part D claims (CY24) · 26K beneficiaries · First FDA approval: 2015-11-13

Brand-only (no generics) 654 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $2.71B

Class share

10%

of class CY24 spend

View profile →

07

Abemaciclib

Brand: Verzenio · 117K Part D claims (CY24) · 22K beneficiaries · First FDA approval: 2017-09-28

Brand-only (no generics) 1308 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $1.76B

Class share

7%

of class CY24 spend

View profile →

08

Lenvatinib

Brand: Lenvima · 59K Part D claims (CY24) · 15K beneficiaries · First FDA approval: 2015-02-13

Brand-only (no generics) 2616 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $1.41B

Class share

5%

of class CY24 spend

View profile →

09

Dasatinib

Brand: PHYRAGO · 75K Part D claims (CY24) · 16K beneficiaries · First FDA approval: 2006-06-27

8 generic mfrs 1992 plans require PA

Low NADAC$29.19

→

Avg plan cost$85.37

Part D spend $850.6M 3× spread, current vs floor

Class share

3%

of class CY24 spend

View profile →

10

Nilotinib

Brand: DANZITEN · 42K Part D claims (CY24) · 7K beneficiaries · First FDA approval: 2007-10-29

5 generic mfrs 1580 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $694.5M

Class share

3%

of class CY24 spend

View profile →

11

Axitinib

Brand: INLYTA · 38K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 2012-01-27

1 generic mfrs 654 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $682.5M

Class share

3%

of class CY24 spend

View profile →

12

Pirtobrutinib

Brand: JAYPIRCA · 18K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 2023-01-27

Brand-only (no generics) 652 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $365.2M

Class share

1%

of class CY24 spend

View profile →

13

Imatinib

Brand: Gleevec · 198K Part D claims (CY24) · 32K beneficiaries · First FDA approval: 2001-05-15

12 generic mfrs 558 plans require PA

Low NADAC$0.827

→

Avg plan cost$1.94

Part D spend $318.0M 2× spread, current vs floor

Class share

1%

of class CY24 spend

View profile →

14

Avapritinib

Brand: Ayvakit · 7K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2020-01-09

Brand-only (no generics) 1635 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $274.6M

Class share

1%

of class CY24 spend

View profile →

15

Everolimus

Brand: Afinitor · 66K Part D claims (CY24) · 14K beneficiaries · First FDA approval: 2009-03-31

10 generic mfrs 4556 plans require PA Discontinued

Low NADAC$2.29

→

Avg plan cost$12.30

Part D spend $259.1M 5× spread, current vs floor

Class share

1%

of class CY24 spend

View profile →

16

Tucatinib

Brand: TUKYSA · 10K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2020-04-17

Brand-only (no generics) 654 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $223.4M

Class share

1%

of class CY24 spend

View profile →

17

Lorlatinib

Brand: Lorbrena · 11K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2018-11-19

Brand-only (no generics) 654 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $209.4M

Class share

1%

of class CY24 spend

View profile →

18

Pacritinib

Brand: Vonjo · 8K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2022-02-28

Brand-only (no generics) 327 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $174.4M

Class share

1%

of class CY24 spend

View profile →

19

Selpercatinib

Brand: RETEVMO · 8K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2020-05-08

Brand-only (no generics) 1308 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $139.8M

Class share

1%

of class CY24 spend

View profile →

20

Ripretinib

Brand: QINLOCK · 3K Part D claims (CY24) · 709 beneficiaries · First FDA approval: 2020-05-15

Brand-only (no generics) 327 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $133.7M

Class share

0%

of class CY24 spend

View profile →

21

Afatinib

Brand: Gilotrif · 8K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2013-07-12

Brand-only (no generics) 981 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $94.9M

Class share

0%

of class CY24 spend

View profile →

22

Crizotinib

Brand: Xalkori · 5K Part D claims (CY24) · 777 beneficiaries · First FDA approval: 2011-08-26

Brand-only (no generics) 1635 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $93.7M

Class share

0%

of class CY24 spend

View profile →

23

Pazopanib

Brand: VOTRIENT · 11K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2016-07-12

6 generic mfrs 331 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $91.6M

Class share

0%

of class CY24 spend

View profile →

24

Brigatinib

Brand: Alunbrig · 4K Part D claims (CY24) · 640 beneficiaries · First FDA approval: 2017-04-28

Brand-only (no generics) 1308 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $71.0M

Class share

0%

of class CY24 spend

View profile →

25

Sunitinib Malate

Brand: SUTENT · 11K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2006-01-26

8 generic mfrs 1308 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $69.0M

Class share

0%

of class CY24 spend

View profile →

26

Larotrectinib

Brand: VITRAKVI · 2K Part D claims (CY24) · 346 beneficiaries · First FDA approval: 2018-11-26

Brand-only (no generics) 981 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $66.7M

Class share

0%

of class CY24 spend

View profile →

27

Pemigatinib

Brand: PEMAZYRE · 2K Part D claims (CY24) · 363 beneficiaries · First FDA approval: 2020-04-17

Brand-only (no generics) 978 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $44.6M

Class share

0%

of class CY24 spend

View profile →

28

Erdafitinib

Brand: BALVERSA · 2K Part D claims (CY24) · 561 beneficiaries · First FDA approval: 2019-04-12

Brand-only (no generics) 978 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $38.2M

Class share

0%

of class CY24 spend

View profile →

29

Sorafenib

Brand: Nexavar · 5K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2005-12-20

5 generic mfrs 327 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $35.9M

Class share

0%

of class CY24 spend

View profile →

30

Selumetinib

Brand: KOSELUGO · 2K Part D claims (CY24) · 284 beneficiaries · First FDA approval: 2020-04-16

Brand-only (no generics) 1304 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $34.6M

Class share

0%

of class CY24 spend

View profile →

31

Lazertinib

Brand: LAZCLUZE · 2K Part D claims (CY24) · 658 beneficiaries · First FDA approval: 2024-08-20

Brand-only (no generics) 654 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $30.9M

Class share

0%

of class CY24 spend

View profile →

32

Pralsetinib

Brand: Gavreto · 2K Part D claims (CY24) · 350 beneficiaries · First FDA approval: 2021-07-01

Brand-only (no generics) 327 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $27.0M

Class share

0%

of class CY24 spend

View profile →

33

Repotrectinib

Brand: Augtyro · 1K Part D claims (CY24) · 338 beneficiaries · First FDA approval: 2023-12-05

Brand-only (no generics) 654 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $22.7M

Class share

0%

of class CY24 spend

View profile →

34

Vemurafenib

Brand: ZELBORAF · 3K Part D claims (CY24) · 631 beneficiaries · First FDA approval: 2011-08-17

Brand-only (no generics) 327 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $22.1M

Class share

0%

of class CY24 spend

View profile →

35

Inavolisib

Brand: Itovebi · 846 Part D claims (CY24) · 327 beneficiaries · First FDA approval: 2024-10-14

Brand-only (no generics) 654 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $18.4M

Class share

0%

of class CY24 spend

View profile →

36

Erlotinib

Brand: Erlotinib · 9K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2019-05-09

8 generic mfrs 957 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $9.9M

Class share

0%

of class CY24 spend

View profile →

37

Idelalisib

Brand: Zydelig · 510 Part D claims (CY24) · 109 beneficiaries · First FDA approval: 2014-07-23

1 generic mfrs 654 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $6.9M

Class share

0%

of class CY24 spend

View profile →

38

Ceritinib

Brand: ZYKADIA · 626 Part D claims (CY24) · 102 beneficiaries · First FDA approval: 2019-03-18

Brand-only (no generics) 325 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $6.9M

Class share

0%

of class CY24 spend

View profile →

39

Gefitinib

Brand: IRESSA · 1K Part D claims (CY24) · 251 beneficiaries · First FDA approval: 2015-07-13

4 generic mfrs 331 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $5.6M

Class share

0%

of class CY24 spend

View profile →

40

Vandetanib

Brand: CAPRELSA · 323 Part D claims (CY24) · 50 beneficiaries · First FDA approval: 2011-07-25

Brand-only (no generics) 648 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $5.3M

Class share

0%

of class CY24 spend

View profile →

41

Mirdametinib

Brand: Gomekli · 133 Part D claims (CY24) · 48 beneficiaries · First FDA approval: 2025-02-11

Brand-only (no generics) 981 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $3.4M

Class share

0%

of class CY24 spend

View profile →

42

Tovorafenib

Brand: OJEMDA · 89 Part D claims (CY24) · 21 beneficiaries · First FDA approval: 2024-04-30

Brand-only (no generics) 1304 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $3.3M

Class share

0%

of class CY24 spend

View profile →

43

Vimseltinib

Brand: ROMVIMZA · 42 Part D claims (CY24) · 17 beneficiaries · First FDA approval: 2025-02-14

Brand-only (no generics) 981 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $1.1M

Class share

0%

of class CY24 spend

View profile →

44

Everolimus Tablets

Brand: Everolimus · — Part D claims (CY24) · First FDA approval: 2021-05-21

Brand-only (no generics)

Low NADAC$2.29

→

Avg plan cost$5.16

Part D spend — 2× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

45

Remibrutinib

Brand: RHAPSIDO · — Part D claims (CY24) · First FDA approval: 2025-09-30

Brand-only (no generics) 4 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

46

Rilzabrutinib

Brand: WAYRILZ · — Part D claims (CY24) · First FDA approval: 2025-08-29

Brand-only (no generics) 2 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

47

Rydapt

— Part D claims (CY24) · First FDA approval: 2017-04-28

Brand-only (no generics) 327 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

48

Zongertinib

Brand: HERNEXEOS · — Part D claims (CY24) · First FDA approval: 2025-08-08

Brand-only (no generics) 326 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

Kinase Inhibitor

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.